Tenderwize
Wróć do wyszukiwania

Open-house rebate agreements for Lopinavir/Ritonavir

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 462 days left·Open·Supplies
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Lopinavir und Ritonavir, ATC J05AR10

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

58 / 100

Czynniki ryzyka

For the first contract start, documents must be received by 31.12.2025; the notice says receipt by the buyer is decisiv...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing Lopinavir and Ritonavir (ATC J05AR10).
  • Supply/contracting scope is limited to medicines that are authorised and marketable in Germany.
Pokaż pełne podsumowanie

This is a non-exclusive open-house supply arrangement for pharmaceutical products containing Lopinavir and Ritonavir (ATC J05AR10) offered by AOK Rheinland-Pfalz/Saarland. The contract period runs from 01.02.2026 to 31.01.2028, with monthly entry possible during the 24-month window. The notice explicitly excludes medicines listed as children’s medicines under the BfArM list (§ 35(5a) SGB V). No contract value is stated. Submission is not electronic-only: paper originals or electronically signed documents by email are allowed, and the notice says the first award/contract conclusion can occur no earlier than 10 days after publication.

Ryzyka

For the first contract start, documents must be received by 31.12.2025; the notice says receipt by the buyer is decisiv...

Only pharmaceutical companies are eligible, and medicines must be authorised and marketable in Germany.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Medicines must be authorised and marketable in Germany.

Eligibility

  • Only pharmaceutical companies are eligible to become contract partners.

Administrative

  • If a product is not listed in Lauer-Taxe at submission time, an AMIce public extract must be provided with specified product and authorisation details.

Zamawiający

Lokalizacja

Eisenberg, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE271900642

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreements for Lopinavir/Ritonavir

Single open-house lot for non-exclusive rebate agreements covering medicines with the active substance Lopinavir and Ritonavir (ATC J05AR10). The buyer states that all interested pharmaceutical companies may join on equal terms, without individual negotiation or selection. Children’s medicines listed in the BfArM list are excluded. Contract duration is up to 24 months, starting no earlier than 01.02.2026, with monthly entry possible. The lot information comes from structured data and notice text.

SuppliesEU fundedElectronic submission

Lokalizacja

Eisenberg, Germany

Czas trwania

Jan 2026 - Jan 2028

Kategoria

Pharmaceutical products

Termin

Deadline Nov 30, 2027

Szczegóły zamówienia

Data publikacji
09 Dec 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
819132-2025

Dokumenty (1)

Podobne przetargi